Peter Boyle, Tessa Holyoake receive Royal Society of Edinburgh Royal Medals

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Peter Boyle

Tessa Holyoake

Peter Boyle, president of the International Prevention Research Institute and director, of the University of Strathclyde Institute of Global Public Health and Tessa Holyoake, director of the Paul O’Gorman Leukaemia Research Centre, Gartnavel General Hospital, Glasgow, received this year’s RSE Royal Medals.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone, also called VRd, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant. A final decision is expected in the coming months.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login